brequinar   Click here for help

GtoPdb Ligand ID: 7406

Synonyms: DUP-785 | DUP785 | NSC 368390 | NSC-368390 | NSC368390
PDB Ligand
Compound class: Synthetic organic
Comment: Brequinar inhibits dihydroorotate dehydrogenase (DHODH), the fourth enzyme in the de novo pyrimidine biosynthesis pathway [2], and it depletes cells of the precursors that are critical for RNA and DNA synthesis [3]. It was developed for potential anti-neoplastic activity. The drug exhibits anti-neoplastic activity against refractory solid tumours in preclinical models, with continuous treatment being necessary to effectively deplete pyrimidine pools in the cancer cells and cause tumour inhibition [1].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 3
Hydrogen bond donors 1
Rotatable bonds 3
Topological polar surface area 50.19
Molecular weight 375.11
XLogP 6.26
No. Lipinski's rules broken 1
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES Fc1ccc2c(c1)c(C(=O)O)c(c(n2)c1ccc(cc1)c1ccccc1F)C
Isomeric SMILES Fc1ccc2c(c1)c(C(=O)O)c(c(n2)c1ccc(cc1)c1ccccc1F)C
InChI InChI=1S/C23H15F2NO2/c1-13-21(23(27)28)18-12-16(24)10-11-20(18)26-22(13)15-8-6-14(7-9-15)17-4-2-3-5-19(17)25/h2-12H,1H3,(H,27,28)
InChI Key PHEZJEYUWHETKO-UHFFFAOYSA-N
No information available.
Summary of Clinical Use Click here for help
Brequinar has been advanced to Phase 1/2 clinical evaluation in patiets with acute myeloid leukemia. With the recognition that DHODH inhibitors can have antiviral activity by limiting the supply of host-produced pyrimidines that viruses need to replicate, brequinar is being evaluated in patients with COVID-19 (the clinical manifestation of SARS-CoV-2 infection).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Brequinar inhibits dihydroorotate dehydrogenase (DHODH), the fourth enzyme in the de novo pyrimidine biosynthesis pathway. Pyrimidines are essential for DNA and RNA synthesis and are therefore crucial for cell growth and division.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04425252 Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19 Phase 1/Phase 2 Interventional Clear Creek Bio, Inc.
NCT03760666 A Study of Brequinar in Subjects With Relapsed/Refractory Acute Myeloid Leukemia Phase 1/Phase 2 Interventional Clear Creek Bio, Inc.